- Cosmetic skincare applications
- Shortest regulatory path
- Increases / enhances skin natural barrier / improved look and feel
- Anti- ageing effect
Partnership with Croda plc- Agreement signed on 20/11/2019
- Specialist cosmetic division Sederma, based in Paris, France
- Large global customer portfolio – 12,000+ Customers
- Building a dedicated production line circa €5mill
- Own label potential
- $100+bn area of high growth (Source: Euromonitor passport stats 2016)
- Food supplement – blend of probiotics for the treatment of skin conditions
- Gut /skin axis
- Exploiting the known relationship between the health of the gut and the skin
- Partnership with Winclove Probiotics
- Agreement signed 19/02/2020
- Based in The Netherlands
- 25 years experience
- Experts in probiotic food supplements
- Multiple application areas
- Psoriasis, $7.0bn with CAGR of 7.0% (Source Reuters 2019)
- Eczema, $3.9bn with CAGR of 3.8% (Source Pharmapoint Global Data 2014)
- Relatively low regulatory requirement
- Requires a short food supplement trial
- Medical Device
- Skin care / enhancing barrier
- Multiple treatment / application areas
- Eczema $3.9bn with CAGR of 3.8% (Source Pharmapoint Global Data 2014)
- Psoriasis $7.0bn with CAGR of 7.0% (Source Reuters 2019)
- Acne $4.9bn with CAGR of 4.6% (Source Persistence Market Research)
- Advanced woundcare / accelerated wound closure
- AWC Market $19.8bn with CAGR of 4.6%
- Protecting inert surfaces by providing a barrier
- Hospital Acquired Infection applications
- Domestic applications
- Prevents “latching” of bacteria
- Skin, surfaces, clothing, sheets, air
- Vulnerable areas
- ICU
- Operating theatres
- Geriatrics / paediatrics
- Healthcare-associated infection $17.1bn CAGR 6.1% (Source: BCC 2015)
- RX / PrescriptionMarket
- Lengthy and complex regulatory path
- Logical follow on from AxisBiotix
- Prescription versions of already established food supplements